Figure 2.

Effects of the allosteric inhibitor (GNF-2) and Abl kinase inhibitor (Dasatinib) on Ba/F3 cells expressing “gatekeeper” mutation T315I. (A) XTT assay using Ba/F3 cells expressing BCR/ABL-T315I upon exposure to 0.3, 0.6, 1.25, 2.5 and 5 μM GNF-2 and 0.3, 0.6, 1.25, 2.5 and 5 μM Dasatinib. Proliferation status was determined by the metabolic activity of cells given by the reduction rate of XTT to formazan. The means +/- SD of triplicates from one representative experiment out of three performed are given. (B) Western blot analysis of Ba/F3 cells expressing the indicated transgenes using antibodies directed against the indicated proteins. (C) Calculation of the combined effect by the MacSynergy program.

Mian et al. BMC Cancer 2012 12:411   doi:10.1186/1471-2407-12-411
Download authors' original image